

ORIC-944

Chemical Properties


CAS No. : 2369769-29-7

Formula: C₂₆H₂₅FN₆O

Molecular Weight: 456.52

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Actual storage temperature shall be subject to the COA.



Biological Description

Description	ORIC-944 is an orally available and selective variant of PRC2 with anticancer activity for prostate cancer research.
Targets(IC50)	Others,Histone Methyltransferase
In vivo	Single agent tumor growth inhibition was observed for ORIC-944 in prostate cancer xenograft models. ORIC-944 also improved ARPI antitumor activity in preclinical combination studies and demonstrated in vitro synergy. [2]

Solubility Information

Solubility	DMSO: 250 mg/mL (547.62 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (21.9 mM),Solution. 10% DMSO+90% Saline: < 10 mg/mL (21.9 mM),Lower concentrations may be soluble, but exact solubility limit is unknown. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.1905 mL	10.9524 mL	21.9048 mL
5 mM	0.4381 mL	2.1905 mL	4.381 mL
10 mM	0.219 mL	1.0952 mL	2.1905 mL
50 mM	0.0438 mL	0.219 mL	0.4381 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Daemen A, et al. ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models[J]. Cancer Research, 2024, 84(6_Supplement): 6586-6586.

Matthew A. Marx, et al. Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer [abstract]. Cancer Res 2024;84(7_Suppl): ND04.

Lori Friedman. Discovery of ORIC-944, a Novel Inhibitor of PRC2 with Best-in-Class Properties for the Treatment of Prostate Cancer.

Anneleen Daemen. ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor with Best-in-Class Properties, Demonstrates Combination Synergy with AR Pathway Inhibitors in Prostate Cancer Models.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 34 Washington Street, Wellesley Hills, MA 02481